Technology
Health
Pharmaceutical

Theravance Biopharma

$24.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.29%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell TBPH and other stocks, options, ETFs, and crypto commission-free!

About

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of small molecule medicines. Read More Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Employees
363
Headquarters
George Town, George Town
Founded
2013
Market Cap
1.34B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
230.35K
High Today
$24.83
Low Today
$23.57
Open Price
$24.15
Volume
68.28K
52 Week High
$35.48
52 Week Low
$21.04

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
North America (Non-US/Canada)
North America

News

Yahoo FinanceMar 13

Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

Theravance Biopharma, Inc. TBPH has dosed the first patient in a phase IIb/III study on its gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is currently being developed in collaboration with Janssen, a subsidiary of Johnson & Johnson JNJ, for treating inflammatory intestinal diseases. The phase IIb dose-finding induction portion of the study will assess the effect of eight weeks of treatment with select once-daily doses of T...

20
Yahoo FinanceFeb 27

Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates

Theravance Biopharma, Inc. TBPH incurred a loss of 92 cents per share in fourth-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of $1.12 and the year-ago loss of $1.64. Total revenues in the quarter under review skyrocketed 248.5% year over year to $15.7 million, mainly on the back of an upfront payment received from Johnson & Johnson JNJ in relation to a joint development agreement for Theravance’s pan-Janus kinase inhibitor, TD-1473. Moreover, the top line surpassed the Zacks Consensus...

19
The Motley FoolFeb 26

Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript

Theravance Biopharma Inc (NASDAQ:TBPH) Q4 2018 Earnings Conference Call , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, good afternoon. At this time, I would like to welcome everyone to the Theravance Biopharma Conference Call. During the presentation, all participants will be in a listen-only mode. A question-and-answer session will follow the Company's formal remarks. (Operator Instructions) Today's conference call...

9

Earnings

-$1.64
-$1.35
-$1.05
-$0.76
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.